论文部分内容阅读
目的:深入了解利拉鲁肽的研究概况,客观反映相关国家、机构和科学家在研究利拉鲁肽的领域中具备的科学能力和影响力。方法:以科学引文索引(SCI)数据库Web of Science为检索平台,以liraglutide or victoza or saxenda“为主题词进行检索,采用文献计量学的方法,分析以利拉鲁肽为主题的相关文献在国家/地区、机构、作者来源、出版物、年发文量、年引文量和引用排名前10名的情况。同时,以中国知网(CNKI)中的中国期刊全文数据库为检索平台,检索以”利拉鲁肽或诺和力“为主题词的所有中文文献并进行文献计量学的分析。时间跨度为1986年1月1日~2015年10月5日。结果:在Web of Science数据库中检索到文献1 596篇,发文量与引文数呈递增趋势,h-index为63;美国和丹麦的研究超过总数的一半以上总被引前10位的SCI文章有7篇为LEAD项目的试验结果,我国发表的SCI文献为110篇;CNKI中收录的中文文章有348篇,10家机构中的9家为综合性的三级甲等医院,发文量最多的为解放军总医院。结论:关于利拉鲁肽的研究,是逐渐上升的趋势,仍是目前研究的热点。中国与国际前沿研究间存在着一定差距。
OBJECTIVE: To understand in depth the research profile of liraglutide and to objectively reflect the scientific capabilities and influence of the countries, institutions and scientists involved in the study of liraglutide. Methods: Using the Web of Science as the search platform and using the term ”liraglutide or victoza or saxenda“ as the retrieval platform, the bibliometric method was used to analyze the related literature with liraglutide Country, institution, author’s source, publication, annual volume, annual quotations and quotations of the top 10. At the same time, the CNKI full-text database of Chinese periodicals was used as the retrieval platform, ”Liraglutide or Novozymes" for all the Chinese literature and bibliometric analysis of time span from January 1, 1986 ~ October 5, 2015. Results: In the Web of Science database 1 596 articles were retrieved, the number of papers published and citations showed an increasing trend with an h-index of 63; more than half of all the studies were conducted in the United States and Denmark. The top 10 most cited articles in the SCI were 7 in the LEAD program , There are 110 SCI articles published in China, 348 Chinese articles contained in CNKI, 9 of 10 institutions are comprehensive Grade-3 Hospitals, and the largest volume of written articles is PLA General Hospital Conclusion: The study of liraglutide is gradual The rising trend is still the hot point of current research.China has a certain gap with the international frontier research.